The American Diabetes Association® (ADA) issued the following statement in response to the House Appropriations Committee’s passage of the Fiscal Year (FY) 2027 funding bill for the Department of Health and Human Services (HHS).
This week, the House Appropriations Committee passed a FY 2027 funding measure that provides incremental funding increases for diabetes research and prevention programs at the National Institutes of Health (NIH) and Centers for Disease Control and Prevention (CDC).
Diabetes is one of the most expensive chronic diseases and is the seventh leading cause of death in the U.S. In fact, one out of every four dollars in U.S. health care is spent on caring for people living with diabetes. Without proper management, diabetes can lead to severe complications including heart disease, kidney failure, amputation, and even death. Obesity is linked to up to 53% of new cases of type 2 diabetes each year. Without treatment, obesity can lead to type 2 diabetes, heart, liver and kidney diseases, and thirteen types of obesity-related cancers among many other costly chronic conditions.
For NIH the bill provides $48.8 billion, which is a $100 million increase over FY26. Additionally, National Institute of Diabetes, Digestive and Kidney Diseases (NIDDK) would receive $2,348,721,000 a $22 million (1%) increase over FY26. Also, the bill does not merge NIDDK with any other institutes or centers.
For CDC the bill provides $873,199,000 in funding for the Center for Chronic Disease Prevention and Health Promotion, where Division of Diabetes Translation (DDT), National Diabetes Prevention Program (National DPP), and Division of Nutrition, Physical Activity and Obesity (DNPAO) are housed. The bill provides $165 million for DDT, a $2 million (1%) increase over FY26. Additionally, $39.3 million is provided for NDPP representing a $2 million (5.4%) increase over FY26. The bill provides $16.5 million for DNPAO representing a $37.8 million (70%) decrease from FY26.
While these funding increases represent a positive step forward, they fall short of the investment needed to meet the growing needs of the more than 40 million Americans living with diabetes and the millions more at risk of developing the disease. The ADA has long advocated for these critical federal investments to address the rising rates of diabetes across the U.S. and its associated costs and protect the progress of recent innovations and biomedical research. The ADA urges Congress to ensure that diabetes research remains a national priority by increasing funding for key diabetes programs across the federal government; we hope the Senate and Congress will advance investments that reflect the impact of diabetes and obesity on our nation.
###
About the American Diabetes Association
The American Diabetes Association (ADA) is the nation’s leading voluntary health organization fighting to end diabetes and helping people thrive. This year, the ADA celebrates 85 years of driving discovery and research to prevent, manage, treat, and ultimately cure diabetes—and we’re not stopping. There are over 155 million Americans living with diabetes or prediabetes. Through advocacy, program development, and education, we’re fighting for them all. To learn more or to get involved, visit us at or call 1-800-DIABETES (800-342-2383). Join us in the fight on Facebook (American Diabetes Association), Spanish Facebook (Asociación Americana de la Diabetes), LinkedIn (American Diabetes Association), and Instagram (@AmDiabetesAssn). To learn more about how we are advocating for everyone affected by diabetes, visit us on X (@AmDiabetesAssn).
